CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials

- October 3rd, 2018

CENTOGENE and Denali Therapeutics (NASDAQ:DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation carrier Parkinson’s disease patients. As quoted in the press release: CENTOGENE will conduct a targeted global recruitment campaign focused on the early identification and characterization of LRRK2 PD patients and sequence the LRRK2 gene in these … Continued

CENTOGENE and Denali Therapeutics (NASDAQ:DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation carrier Parkinson’s disease patients.

As quoted in the press release:

CENTOGENE will conduct a targeted global recruitment campaign focused on the early identification and characterization of LRRK2 PD patients and sequence the LRRK2 gene in these patients. Under the terms of the agreement, CENTOGENE will utilize CentoCard, its proprietary, validated, dried blood spot collection kit, to identify PD patients with a mutation in the LRRK2 gene for recruitment into Denali’s clinical trials.

Mutations in the LRRK2 gene are one of the most commonly known genetic causes of Parkinson’s disease and a driver of lysosomal dysfunction, which contributes to the formation of Lewy body protein aggregates and neurodegeneration.

“Our exclusive collaboration underscores CENTOGENE’s strong capability to accelerate the early identification of patients with rare genetic diseases worldwide. As a leader in providing genetic insights in rare diseases, we believe we can contribute to Denali’s development of disease modifying medicines for patients with Parkinson’s disease. CENTOGENE will help Denali speed up the enrollment of patients in clinical studies for its LRRK2 program,” said Dr. Arndt Rolfs, CEO and founder of CENTOGENE.

Click here to read the full press release.

Find out what experts are saying about the future of cannabis


Read our new report today

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *